NUVL Stock Analysis: Nuvalent | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.783m USD | 12M Return: 58.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 321M
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nuvalent, Inc. (NUVL) is a clinical-stage biopharmaceutical company developing precision oncology therapies for patients with cancer. Its pipeline is led by three small-molecule candidates designed to address treatment resistance and brain metastases in lung cancer: Zidesamtinib (NVL-520), a ROS1-selective inhibitor in the Phase 2 portion of the ARROS-1 trial for ROS1-positive NSCLC; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor in the Phase 2 portion of the ALKOVE-1 trial; and NVL-330, a HER2-selective inhibitor in Phase 1a/1b development targeting HER2 exon 20 insertion-driven tumors. The company maintains a strategic partnership with Guardant Health to develop companion diagnostics, supporting its precision medicine approach. Incorporated in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent operates within the biotechnology subsector of healthcare.
As a clinical-stage biopharmaceutical company, Nuvalent has not yet commercialized a product and its valuation is primarily tied to pipeline progress, clinical trial outcomes, and capital-raising capacity rather than recurring revenue. The partnership with Guardant Health reflects a broader industry shift toward integrating molecular diagnostics with targeted therapies, helping identify patients most likely to respond to selective kinase inhibitors.
- ARROS-1 Phase 2 NVL-520 readout in ROS1 NSCLC
- ALKOVE-1 NVL-655 data against competing ALK inhibitors
- Cash runway and financing plans as clinical burn accelerates
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -5.07 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -312.8m > Net Income -450.1m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 16.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.7m) vs 12m ago 9.86% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.92 (Total Current Assets 1.31b - Total Current Liabilities 81.1m) / Total Assets 1.33b |
| B: -0.81 (Retained Earnings -1.08b / Total Assets 1.33b) |
| C: -0.36 (EBIT TTM -438.9m / Avg Total Assets 1.22b) |
| D: 7.49 (Book Value of Equity 1.17b / Total Liabilities 156.8m) |
| Altman-Z'' = 8.84 = AAA |
As of July 08, 2026, the stock is trading at USD 123.77 with a total of 1,077,918 shares traded. Over the past week, the price has changed by +0.21%, over one month by +39.87%, over three months by +21.05% and over the past year by +58.82%.
Current recommended Stop Loss: 121.10 (which is 2.2% or 1.3 ATR below the current price).
Nuvalent has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy NUVL.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 125.1 | 1.1% |
P/B = 8.3281
Revenue TTM = 0.0 USD
EBIT TTM = -438.9m USD
EBITDA TTM = -24.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 8.50b USD (9.78b + (null Debt) - CCE 1.29b)
Interest Coverage Ratio = unknown (Ebit TTM -438.9m / Interest Expense TTM 0.0)
EV/FCF = -27.16x (Enterprise Value 8.50b / FCF TTM -312.8m)
FCF Yield = -3.68% (FCF TTM -312.8m / Enterprise Value 8.50b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 6.38 (Enterprise Value 8.50b / Total Assets 1.33b)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -346.7m (EBIT -438.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.14 (Total Current Assets 1.31b / Total Current Liabilities 81.1m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -24.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM -312.8m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -36.94% (Net Income -450.1m / Total Assets 1.33b)
RoE = -42.78% (Net Income TTM -450.1m / Total Stockholder Equity 1.05b)
RoCE = -35.11% (EBIT -438.9m / Capital Employed (Total Assets 1.33b - Current Liab 81.1m))
RoIC = -27.74% (negative operating profit) (NOPAT -346.7m / Invested Capital 1.25b)
WACC = 8.33% (E(9.78b)/V(9.78b) * Re(8.33%) + (debt-free company))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 11.02%
[DCF] Fair Price = unknown (Cash Flow -312.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.33 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.37 | Chg30d=+1.11% | Revisions=+0% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-1.39 | Chg30d=+0.73% | Revisions=+0% | Analysts=15
EPS current Year (2026-12-31): EPS=-5.48 | Chg30d=+0.06% | Revisions=+0% | GrowthEPS=+6.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.13 | Chg30d=-0.75% | Revisions=+6% | GrowthEPS=+24.5% | GrowthRev=+1573.1%
[Analyst] Revisions Ratio: +2% (up=27, down=26)